Comparison of Short- and Long-Term Mortality in Patients with or without Cancer Admitted to the ICU for Septic Shock: A Retrospective Observational Study.
critical care
immunocompromised host
neoplasms
septic shock
treatment outcome
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jun 2022
29 Jun 2022
Historique:
received:
10
06
2022
revised:
27
06
2022
accepted:
28
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
10
7
2022
Statut:
epublish
Résumé
Introduction: Cancer patients are at high risk of developing septic shock (SSh) and are increasingly admitted to ICU given their improved long-term prognosis. We, therefore, compared the prognosis of cancer and non-cancer patients with SSh. Methods: We conducted a monocentric, retrospective cohort study (2013−2019) on patients admitted to ICU for SSh. We compared the clinical characteristics and management and studied short- and long-term mortality with ICU and in-hospital mortality and 1-year survival according to cancer status. Results: We analyzed 239 ICU stays in 210 patients, 59.5% of whom were men (n = 125), with a median age of 66.5 (IQR 56.3−77.0). Of the 121 cancer patients (57.6% of all patients), 70 had solid tumors (33.3%), and 51 had hematological malignancies (24.3%). When comparing ICU stays of patients with versus without cancer (n = 148 vs. n = 91 stays, respectively), mortality reached 30.4% (n = 45) vs. 30.0% (n = 27) in the ICU (p = 0.95), and 41.6% (n = 59) vs. 35.6% (n = 32) in hospital (p = 0.36), respectively. ICU length of stay (LOS) was 5.0 (2.0−11.3) vs. 6.0 (3.0−15.0) days (p = 0.27), whereas in-hospital LOS was 25.5 (13.8−42.0) vs. 19.5 (10.8−41.0) days (p = 0.33). Upon multivariate analysis, renal replacement therapy (OR = 2.29, CI95%: 1.06−4.93, p = 0.03), disseminated intravascular coagulation (OR = 5.89, CI95%: 2.49−13.92, p < 0.01), and mechanical ventilation (OR = 7.85, CI95%: 2.90−21.20, p < 0.01) were associated with ICU mortality, whereas malignancy, hematological, or solid tumors were not (OR = 1.41, CI95%: 0.65−3.04; p = 0.38). Similarly, overall cancer status was not associated with in-hospital mortality (OR = 1.99, CI95%: 0.98−4.03, p = 0.06); however, solid cancers were associated with increased in-hospital mortality (OR = 2.52, CI95%: 1.12−5.67, p = 0.03). Lastly, mortality was not significantly different at 365-day follow-up between patients with and without cancer. Conclusions: In-hospital and ICU mortality, as well as LOS, were not different in SSh patients with and without cancer, suggesting that malignancies should no longer be considered a barrier to ICU admission.
Identifiants
pubmed: 35804966
pii: cancers14133196
doi: 10.3390/cancers14133196
pmc: PMC9264783
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Crit Care Med. 2012 Jan;40(1):43-9
pubmed: 21926615
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Ann Oncol. 2017 Feb 1;28(2):400-407
pubmed: 27831506
Crit Care Med. 2012 Jan;40(1):55-62
pubmed: 21926606
PLoS One. 2020 Dec 28;15(12):e0243449
pubmed: 33370330
BMJ Open. 2021 Feb 16;11(2):e038349
pubmed: 33593761
Ann Intensive Care. 2011 Mar 23;1(1):5
pubmed: 21906331
Crit Care Med. 2008 Mar;36(3):690-6
pubmed: 18431262
Crit Care Med. 2017 Dec;45(12):2031-2039
pubmed: 28937407
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Support Care Cancer. 2020 Mar;28(3):1325-1333
pubmed: 31243586
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
Support Care Cancer. 2019 Jul;27(7):2413-2424
pubmed: 30993453
Intensive Care Med. 2019 Jul;45(7):977-987
pubmed: 31143998
Crit Care. 2004 Oct;8(5):R291-8
pubmed: 15469571
Curr Opin Crit Care. 2011 Apr;17(2):153-9
pubmed: 21346564
Aust N Z J Public Health. 2020 Feb;44(1):53-58
pubmed: 31535416
Intensive Care Med. 2016 Jun;42(6):1062-4
pubmed: 26858172
Chest. 2006 Jun;129(6):1432-40
pubmed: 16778259
Crit Care Med. 2019 Oct;47(10):1310-1316
pubmed: 31356477
Am J Respir Cell Mol Biol. 2021 Aug;65(2):167-175
pubmed: 33798037
Cancer Immunol Immunother. 2016 Jul;65(7):813-9
pubmed: 26910314
Crit Care Med. 2020 Jun;48(6):822-829
pubmed: 32317596
Crit Care Med. 1981 Aug;9(8):591-7
pubmed: 7261642
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Intensive Care Med. 2017 Sep;43(9):1366-1382
pubmed: 28725926
Cancer Med. 2020 Jun;9(11):3765-3774
pubmed: 32281275
Clin Adv Hematol Oncol. 2012 Dec;10(12):825-6
pubmed: 23271355
Intensive Care Med. 2003 Oct;29(10):1688-95
pubmed: 13680115
Front Med (Lausanne). 2021 Apr 26;8:603275
pubmed: 33981712
Chest. 2014 Nov;146(5):1205-1213
pubmed: 25033349
Oncotarget. 2017 Jan 3;8(1):1860-1870
pubmed: 27661125
J Crit Care. 2012 Jun;27(3):301-7
pubmed: 21855281
Virulence. 2014 Jan 1;5(1):36-44
pubmed: 23774844
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Cancer Treat Res. 2014;161:43-89
pubmed: 24706221
Crit Care. 2019 May 31;23(1):196
pubmed: 31151462
Ann Am Thorac Soc. 2015 Aug;12(8):1185-92
pubmed: 26086679
Ann Hematol. 2019 May;98(5):1051-1069
pubmed: 30796468
Clin Infect Dis. 2014 Nov 15;59 Suppl 5:S360-4
pubmed: 25352632